酪氨酸激酶抑制剂耐药的慢性髓性白血病患者BCR-ABL激酶区突变相关变量分析
回顾性分析2001年6月至2019年9月北京大学人民医院804例CML患者发生的1093例次TKI耐药,采用Sanger测序检测BCR-ABL激酶区突变。伊马替尼、尼洛替尼、达沙替尼耐药患者突变检出率分别为50.5%、63.9%、57.3%,T315I突变检出率均最高。多因素分析显示无TKI减停用药史是突变检出的共同相关因素。
要点
- TKI耐药CML患者中半数以上可检出BCR-ABL突变,T315I为最常见突变类型。
- 无TKI减停用药史是伊马替尼、尼洛替尼、达沙替尼耐药患者发生BCR-ABL突变的共同相关因素。
- 男性、年龄小、无共存疾病、进展期、继发耐药等与较高比例检出BCR-ABL突变相关。
核心结论
- CML患者发生TKI耐药时,半数以上可检测出BCR-ABL突变,其中T315I突变比例最高。
- 人口学、疾病状态和TKI用药等临床特征与BCR-ABL突变的检出率和类型相关。
研究设计与样本
- 回顾性分析2001年6月至2019年9月就诊于北京大学人民医院并发生TKI耐药的CML患者。
- 共纳入804例CML患者,发生1093例次TKI耐药,其中伊马替尼576例次(52.7%)、尼洛替尼238例次(21.8%)、达沙替尼279例次(25.5%)。
- 采用Sanger测序法检测BCR-ABL激酶区突变,二元Logistic回归模型进行多因素分析。
主要发现
- 伊马替尼、尼洛替尼和达沙替尼耐药患者BCR-ABL突变检出率分别为50.5%、63.9%和57.3%。
- T315I突变在伊马替尼、尼洛替尼和达沙替尼耐药患者中检出率均最高,分别为12.3%、27.3%和34.1%。
- 检出率≥5%的突变类型:伊马替尼耐药为Y253F/H(7.5%)和F359V/C/I(5.6%);尼洛替尼耐药为F359V/C/I(12.2%)、Y253F/H(11.8%)和E255K/V(10.5%);达沙替尼耐药为F317L/V/I/C(11.5%)和E255K/V(5.4%)。
- 多因素分析显示无TKI减停用药史是影响BCR-ABL突变检出的共同因素,无TKI减停用药史患者突变检出率更高。
- 男性、年龄小、无共存疾病、诊断至服用当前TKI间隔较长、开始服用当前TKI时为进展期、继发耐药、耐药时处于进展期或血液学耐药与较高比例检出BCR-ABL突变相关。
临床怎么用
- 原文结论认为,与BCR-ABL突变检出显著相关的临床变量不仅应作为后续TKI选择的依据,也有助于理解TKI耐药机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To explore BCR-ABL kinase domain mutation profiles and clinical variables associated with them in tyrosine kinase inhibitor (TKI) -resistant patients with chronic myeloid leukemia (CML) . Methods: Imatinib-, nilotinib-, and/or dasatinib-resistant patients with CML who screened BCR-ABL mutation (s) in Peking University People's Hospital between June 2001 and September 2019 were retrospectively reviewed. BCR-ABL mutation was analyzed by Sanger sequencing. Binary logistic regression model was built to identify independent clinical variables associated with developing BCR-ABL mutation (s) . Results: Data of 1 093 TKI-resistant cases in 804 patients who experienced resistance to imatinib (n=576, 52.7%) , nilotinib (n=238, 21.8%) , and dasatinib (n=279, 25.5%) were analyzed. In total, 291 (50.5%) imatinib-, 152 (63.9%) nilotinib-, and 160 (57.3%) dasatinib-resistant cases developed BCR-ABL mutation (s) . T315I mutation was the most frequent mutation detected in imatinib-, nilotinib-, and dasatinib-resistant cases, accounting for 12.3%, 27.3%, and 34.1%, respectively. Y253F/H (7.5%) and F359V/C/I (5.6%) were the mutation detected in ≥5% imatinib-resistant cases; F359V/C/I (12.2%) , Y253F/H (11.8%) , and E255K/V (10.5%) in nilotinib-resistant cases; and F317L/V/I/C (11.5%) and E255K/V (5.4%) in dasatinib-resistant cases. In multivariate analyses, no TKI dose reduction or discontinuation of TKI therapy was the common variable associated with developing BCR-ABL mutation (s) . Other variables associated with developing BCR-ABL mutation (s) in imatinib-, nilotinib-, or dasatinib-resistant cases included male gender, younger age, no comorbidity, advanced phase before starting current TKI therapy, longer interval from diagnosis to starting current TKI therapy, acquired resistance, and TKI resistance due to progression to advanced phase or hematologic failure. In addition, interval from TKI failure to BCR-ABL mutation detection, starting initial TKI therapy to TKI failure, and starting current TKI therapy to TKI failure were associated with the frequency of developing BCR-ABL mutation. Dasatinib and nilotinib use and acquired resistance were identified to be associated with the development of T315I mutation in multivariate analyses. Conclusions: More than half of TKI-resistant CML patients developed BCR-ABL mutation (s) by Sanger sequencing. T315I mutation was the most frequently detected. Clinical variables significantly associated with developing BCR-ABL mutation (s) should be used not only as basis for the choice of subsequent TKIs but also the understanding of TKI-resistant mechanisms. 目的: 分析酪氨酸激酶抑制剂(TKI)耐药的慢性髓性白血病(CML)患者BCR-ABL激酶区突变状况、类型和影响因素。 方法: 回顾性分析2001年6月至2019年9月就诊于北京大学人民医院并发生TKI耐药的CML患者的BCR-ABL激酶区突变状况。采用Sanger测序法检测BCR-ABL激酶区突变,二元Logistic回归模型进行多因素分析。 结果: 共纳入804例CML患者,发生1 093例次TKI耐药,其中对伊马替尼、尼洛替尼、达沙替尼耐药分别为576(52.7%)、238(21.8%)、279(25.5%)例次。伊马替尼、尼洛替尼和达沙替尼耐药患者BCR-ABL突变检出率分别为50.5%、63.9%和57.3%,T315I突变检出率均最高,分别为12.3%、27.3%和34.1%。此外,检出率≥5%的突变类型在伊马替尼耐药患者中为Y253F/H(7.5%)和F359V/C/I(5.6%),在尼洛替尼耐药患者中为F359V/C/I(12.2%)、Y253F/H(11.8%)和E255K/V(10.5%),在达沙替尼耐药患者中为F317L/V/I/C(11.5%)和E255K/V(5.4%)。多因素分析显示,TKI减停用药史是影响BCR-ABL突变检出的共同因素,无TKI减停用药史患者突变检出率更高。此外,男性、年龄小、无共存疾病、诊断至服用当前TKI间隔较长、开始服用当前TKI时为进展期、继发耐药、耐药时处于进展期或血液学耐药与较高比例检出BCR-ABL突变相关。发生治疗失败至筛查BCR-ABL突变时间间隔、耐药时当前TKI和总TKI服用时间也与突变检出率相关。服用达沙替尼或尼洛替尼、继发耐药与检出T315I突变相关。 结论: CML患者发生TKI耐药时,半数以上的患者检测出BCR-ABL突变,其中T315I突变比例最高,人口学、疾病状态和TKI用药等临床特征与BCR-ABL突变的检出率和类型相关。.
引用
- Shi DY, Qin YZ, Lai YY, et al. [Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32654459. doi:10.3760/cma.j.issn.0253-2727.2020.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。